VPT therapy shows ray of hope for prostate cancer patients

VPT therapy shows ray of hope for prostate cancer patients

Showing a new ray of hope for prostrate cancer patient, a team of doctors have successfully demonstrated how injecting a light-sensitive drug into the patient’s bloodstream and then activating it using a laser can destroy tumor tissue in the low-risk prostate.

In a phase-3 trial, the new approach called Vascular-Targeted Photodynamic (VTP) therapy was found successful in achieving complete remission of tumor in half of the men who were treated in the trial.

Senior author Mark Emberton, dean of medical sciences & consultant urologist at University College London in the UK, said, “These results are excellent news for men with early, localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate.”

Dr. Stephen Freedland, Los Angeles, Calif.-based Cedars-Sinai Medical Center, called the VTP therapy a “novel, interesting” treatment to cure prostate cancer patients, but he also warned that that the results of the trial didn’t justify the routine use of the new approach for all prostate cancer patients.

The new approach to treat low-risk prostate cancer was published in the most recent edition of the journal Lancet Oncology.



Whether you want to ask us a question, would like to solve a problem, or just give us a suggestion, you’ll find many ways to contact us right here.

Email: editor@norcal.news

Phone: (916) 225-9835

Fax: (916) 225-9845


Subscribe and get the latest updates, news and more...